The biopharmaceutical company Viking Therapeutics finds itself at a pivotal operational crossroads. While it has laid extensive industrial groundwork for a 2026 commercial launch, recent analyst caution highlights the clinical uncertainties that still dominate its near-term trajectory. This tension between long-term preparation and imminent binary data events defines the current investment thesis.
Manufacturing Scale Meets Clinical Scrutiny
In a significant move to secure future supply, Viking has entered into a multi-year agreement with the leading contract development and manufacturing organization (CDMO), CordenPharma. The deal is designed to support the production of over one billion oral tablets and 100 million auto-injectors annually, covering both active pharmaceutical ingredients and final fill-finish services for injectable and oral formulations. This framework positions the company for potential high-volume production starting in 2026.
However, this operational confidence was tempered this week by a shift in analyst sentiment. One market strategist downgraded the firm’s rating from “Buy” to “Hold,” citing intensifying competition in the GLP-1 drug segment and the binary risk associated with upcoming Phase 3 trial results. The advice to investors is to await further clinical data before establishing new positions.
A Cascade of Catalysts on the Horizon
The company’s clinical strategy is centered on VK2735, a dual GLP-1/GIP agonist being developed for obesity. Two Phase 3 studies for the subcutaneous formulation (the VANQUISH program) are already underway. Management has outlined plans to initiate a Phase 3 trial for the oral version in the third quarter of 2026. Notably, this oral study is designed to require 75% fewer participants than the subcutaneous programs, implying a substantially lower cost profile. Company leadership has expressed confidence in meeting this timeline.
Financially, Viking ended 2025 with $706 million in cash and liquid assets, a decrease from the $903 million reported at the close of 2024. This reduction aligns with a marked increase in research and development spending, which reached $153.5 million in the fourth quarter of 2025, up sharply from $31.0 million in the comparable period a year earlier. This expenditure surge is directly tied to the operational costs of running two major clinical trials. The company has reiterated that its current cash reserves are sufficient to fund operations through several critical upcoming milestones.
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
The Immediate Focus: Maintenance Study Data
Before the conclusive Phase 3 results arrive, the market is anticipating data from an ongoing maintenance study. This trial involves approximately 180 participants with a BMI of at least 30. After an initial 19-week treatment period, subjects were randomized to various dosing regimens, including monthly, bi-weekly, and daily administrations via both subcutaneous and oral routes. Results are expected in Q3 2026.
These findings carry strategic weight, as they may offer early insights into the tolerability and efficacy of the oral formulation ahead of the full Phase 3 readout.
A Defining Period Approaches
The third quarter of 2026 is shaping up to be the most data-rich period in the company’s history. It is slated to include the maintenance study results, continued patient recruitment for the VANQUISH trials, the launch of the oral Phase 3 study, and potentially the first dosing in Viking’s amylin program. The coming months will determine whether the clinical outcomes can justify the substantial infrastructure already being put in place.
Despite posting a larger-than-expected loss in its last quarterly report, Viking’s share price appreciated by 16.3% following the earnings release. Institutional interest remains, evidenced by ACT Capital’s acquisition of 206,100 shares during the fourth quarter of 2025. The path forward now hinges squarely on the clinical data soon to be unveiled.
Ad
Viking Therapeutics Stock: Buy or Sell?! New Viking Therapeutics Analysis from March 22 delivers the answer:
The latest Viking Therapeutics figures speak for themselves: Urgent action needed for Viking Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 22.
Viking Therapeutics: Buy or sell? Read more here...
